Johnson & Johnson

This proposal asks shareholders to cast a non-binding, advisory vote to approve the Company’s named executive officer compensation as described in the Compensation Discussion and Analysis (CD&A). Management is seeking shareholder approval to affirm its pay-for-performance philosophy: a compensation mix heavily weighted toward performance-based long-term incentives (PSUs, options and RSUs) tied to multi-year EPS and relative TSR metrics, supplemented by annual incentives that are 70% financial and 30% strategic. The Compensation & Benefits Committee oversees design and outcomes and engaged an independent consultant; the Committee exercised discretion in excluding certain special items from incentive metrics (notably excluding the $7.0 billion talc settlement charge reversal from 2025 incentive calculations) to avoid windfalls or penalties outside executives’ control. The program includes governance features such as capped incentive payouts (0–200%), stock ownership guidelines, clawback/recoupment policies, no hedging or pledging, and annual Say-on-Pay votes to maintain alignment with shareholders. Management highlights strong 2025 company performance (financial and strategic), prior-year Say-on-Pay support (~92% in 2025), and extensive shareholder engagement as reasons for support. A vote FOR would indicate shareholder endorsement of the Company’s executive pay philosophy and recent compensation outcomes; the vote is advisory and not binding on the Board. The Board recommends FOR, noting that most CEO and NEO pay is at risk and linked to long-term performance measures intended to align management incentives with shareholder value creation. Key contextual issues for an analyst include the Board’s discretion to adjust outcomes for special items, the use of non-GAAP metrics for incentive determinations, the interaction between multi-year PSUs and overlapping TSR/EPS cycles, and the Company’s handling of litigation-related accounting items in compensation decisions. Given the Company’s recent strong operational results and the Board’s robust disclosure on pay governance, management argues that its program appropriately balances retention, incentives and alignment with shareholder interests.

The shareholder proposal requests that Johnson & Johnson adopt a binding policy (and amend bylaws if necessary) requiring the Board Chair be an independent director, with limited waivers if no independent director is available. The proponent (The Accountability Board, Inc.) argues that separating the Chair and CEO would strengthen Board oversight and accountability, citing prior near-passing shareholder support (~43% in 2021) and asserting recent underperformance versus relevant indices as a justification for change. The requested policy is prescriptive—requiring replacement of a Chair who ceases to be independent—and is aimed at institutionalizing a governance norm favored by many proxy advisors and investors. Management and the Board counter that a forced separation would reduce the Board’s flexibility to select the individual best suited to lead given the Company’s unique circumstances, and emphasize that a robust Lead Independent Director role and fully independent Board committees already deliver independent oversight. The Board also stresses its regular shareholder engagement, consideration of market practices, and the corporate governance processes (committee oversight, executive sessions, CEO performance reviews and succession planning) it maintains to protect shareholder interests. For a governance analyst, key considerations include (1) the non-binding nature of the shareholder proposal and the Board’s entrenched preference for flexibility; (2) the Company’s argument that a strong Lead Independent Director can materially replicate the oversight benefits of an independent chair; (3) the record of shareholder engagement and prior vote results indicating evolving investor sentiment on leadership structure; (4) potential impacts on board dynamics, succession planning, and crisis management should the roles be separated; and (5) the broader market trend toward independent chairs at many large corporations. The Board’s opposition emphasizes contextual judgment and operational continuity, while proponents point to accountability and alignment with governance best practices—making this a classic governance trade-off for investors evaluating board leadership reform.